Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia

Leukemia Research Reports

卷:17

Ruiko Yamano¹  Noriharu Nakagawa²  Yukio Kondo³  Sayaka Kajikawa³  Hirokazu Okumura³ 

[1] Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan;

[2] Corresponding author.;

关键词: Primary DLBCL of the CNS;    Tirabrutinib;    ASCT;    Comorbidity;   

DOI  :  

来源: DOAJ

【 摘 要 】

The optimal therapy for relapsed primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) remains unclear. We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT). Tirabrutinib is well tolerated and effective for relapsed primary DLBCL of the CNS with comorbidities, including cirrhosis and pancytopenia. Tirabrutinib is a promising option as bridging therapy before ASCT.

【 授权许可】

Unknown